Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_3

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

NCT03079063
completed

Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

NCT03251547
completedphase_3

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

NCT00375323

Clinical Trials (3)

Showing 3 of 3 trials
NCT03079063Phase 3

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

Completed
NCT03251547

Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Completed
NCT00375323Phase 3

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3